Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more

Does Maintenance Rucaparib Improve Post-Progression Outcomes in Ovarian Cancer?

June 10, 2019 7:00 pm

By Dave Levitan

Maintenance therapy with the PARP inhibitor rucaparib offered improved post-progression outcomes in a phase III trial of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in a complete or partial response to … Read more

SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer

June 5, 2019 8:00 pm

By Leah Lawrence

Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more

Chemo-Free Combo Boosts PFS in Recurrent Ovarian Cancer

June 4, 2019 6:00 pm

By Ian Ingram

Benefit seen across all subgroups for patients with platinum-sensitive disease.

Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more

Choosing Sides: Treatment Decisions for Recurrent Ovarian Cancer Must Consider Side Effects

May 30, 2019 6:00 pm

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects.

Luckily, doctors have a variety of ways to relieve or prevent these discomforts.

Read more

Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

March 26, 2019 5:00 pm

IMV Inc., a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key … Read more

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer

March 22, 2019 5:00 pm

By Christina Bennett, MS

Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer

March 17, 2019 6:00 pm

By Ian Ingram

In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.

Compared with placebo, … Read more

SGO 2019: Dendritic Cell-Based Immunotherapy Appears Promising for Recurrent Ovarian Cancer

March 16, 2019 5:00 pm

The treatment offers long-lasting anti-tumor immunity.

The addition of a dendritic cell immunotherapy to chemotherapy has been found to prolong overall survival significantly in patients with recurrent ovarian cancer. The combination of chemotherapy + immunotherapy corresponded to 73% survival after … Read more

Clearity’s Scientific Director, Dr. Deb Zajchowski, Presents Poster at SGO: Genomic Mutation Profiles of Paired Ovarian Cancers Across Time

March 16, 2019 9:00 am

Clearity’s Scientific Director, Dr. Deb Zajchowski, presented a poster at the SGO’s 50th Annual Meeting on Women’s Cancers entitled: Genomic Mutation Profiles of Paired Ovarian Cancers Across Time.

The data presented describes some of the research being done utilizing The … Read more

Tackling Cancer Anxiety

November 18, 2018 6:29 pm

By Susan Gubar

No matter how long I deal with periodic blood tests, abdominal CTs and mammograms, they always trigger a huge wave of ‘scanxiety.’

Last year, right before the winter holidays, the nurse practitioner palpating my breast paused and … Read more

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years

October 22, 2018 4:35 pm

By 

A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.

Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more

To Test or Not To Test: A Thorny Question in Ovarian Cancer Maintenance

September 19, 2018 9:28 pm

BY Kelly Irvin

I’ve officially entered the twilight zone. No, not the one Rod Serling spoke of on that classic TV show. This is that murky, dark period when the tumor markers associated with ovarian cancer start creeping up. While … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more